Despite the fact that metastasis is the leading cause of cancerrelated deaths, many of the cellular and molecular mechanisms that drive this process remain poorly understood. Metastasis is the sequence of events by which cancer spreads from the primary tumor via hematogenous or lymphatic dissemination, resulting in downstream colonization at remote, secondary sites, often the liver, lung, brain or bone marrow 1 . This complex cascade of events is initiated by the invasion of primary tumor cells into surrounding tissues and entry into the vasculature, followed by transport and intravascular arrest at a distant site, extravasation and, finally, cell proliferation and formation of metastatic foci.
easy-to-use in vitro microfluidic-based assay featuring perfusable µVNs. The user can achieve rapid and robust quantification of tumor cell extravasation efficiency, and if required perform higher-spatiotemporal-resolution imaging of the morphological dynamics of tumor and endothelial cells during transmigration. The protocol consists of five sequential components: (i) device fabrication and sterilization, (ii) injection of endothelial and fibroblast-cell-laden fibrin gels, (iii) device culture until formation of perfusable µVNs, (iv) perfusion of tumor cells and (v) live tracking of tumor cell extravasation and data analysis.
Device fabrication and mVN formation (Steps 1-12).
The device features three hydrogel regions (each 800 µm wide × 1,300 µm long × 110 µm high), each separated by media channels that allow delivery and exchange of soluble factors and small particles. Upright microposts separated by 100 µm delineate the boundaries of each gel region, simultaneously allowing surface-tensionassisted filling of cell-laden hydrogels and paracrine interactions between endothelial cells and flanking fibroblasts. Human umbilical vein endothelial cells (HUVECs) and human lung fibroblasts (FBs) suspended in fibrin gels are injected into the central and side gel regions, respectively (Fig. 1) . During device culture, single HUVECs elongate, form vacuoles and connect with neighboring cells to form patent lumens within 4-5 d (Fig. 2a) . Paracrine signaling from fibroblasts in the flanking gel regions help to prevent the premature regression of µVNs (as compared with HUVEC monoculture) 4 , such that the characterization of extravasation events is not affected by changes in network morphology. The number of devices seeded per experiment is up to the discretion of the user-we have conclusively shown that 36 independent devices can be seeded in one sitting without compromising cell viability. Although it is possible for human microvascular endothelial cells (HMVECs) to be used instead of HUVECs, we have observed that the current protocol with HMVECs yields substantially less perfusable and less interconnected vascular networks. Further optimization of the initial extracellular matrix (ECM) composition and exogenous growth factors is required if HMVEC culture is desired.
Perfusion of tumor cells (Steps 13-19).
Vasculogenesis-like tube formation in hydrogels has long been demonstrated in a variety of assays, including those for gel droplets and endothelial cell spheroids 5, 6 . However, while microvessels form, most systems remain unperfusable because of the lack of accessible entry points into the vasculature. In our assay, the device is designed such that the µVNs form open lumens that connect with the media channels via the space between microposts (Fig. 2b) . Similar designs in microfluidics have been widely used to allow vascular network formation followed by perfusion to study endothelial barrier function [7] [8] [9] . In this setup, tumor cells suspended in medium can be perfused into µVNs by applying a hydrostatic pressure drop (~4 mm H 2 O) across the HUVEC gel region, which results in physiologically relevant fluid shear stresses (~1 Pa). Details in the determination of average shear stress can be found in Supplementary Figure 1 . During ~10 min of perfusion via a hydrostatic pressure drop, both single cells and aggregates of tumor cells physically lodge in and/or adhere to the endothelium (Fig. 2c) . At times, tumor cells can lodge and dislodge multiple times throughout the network before permanently arresting, similar to in vivo observations 10 . In the case of tumor cells with diameters of ~15-20 µm, >80% of tumor cells arrested in the networks are physically lodged, rather than purely adhered. At our seeding densities, the number of arrested tumor cells per device generally ranges between 40 and 150 cells. This depends on several factors, including average vessel diameter, tumor cell diameter, duration of perfusion and degree of perfusability of the µVNs.
Rapid quantification of extravasation efficiency (Steps 29-31).
Cells are scored as extravasated if the entire tumor cell body is found outside of the lumen. These can be clearly differentiated from mid-transmigrating and fully intravascular cells. The thin height of the hydrogel region causes µVNs to be confined largely to a single plane, greatly increasing the speed of imaging and enabling accurate extravasation scoring (Fig. 3a, Supplementary  Fig. 2 ). Tumor cells are typically found to initiate transendothelial migration within 2-6 h post injection, and a fraction of these can complete transmigration anywhere between 4 and 48 h, depending on the tumor cell type and/or treatments applied (Fig. 3b,c) . In addition, the extravasation behavior of different subpopulations of cells within a single device can be studied-for instance, the extravasation potential of single tumor cells versus tumor cells clusters can be differentiated (Fig. 3d,e) .
If desired, the user can impose a constant flow of medium through the µVNs to simulate the flow condition in vivo throughout the entire extravasation process. This can be achieved via hydrostatic pressures generated from integrated reservoirs (typically for <6 h before substantial equilibration), or for longer durations using syringe pumps. Extravasation efficiency can be assessed at a specific end point or over time via live confocal microscopy. At 20× magnification, imaging of an entire device typically takes 6-12 min, depending on the imaging modality and Table 1 ). Images are later reconstructed in 3D using standard software packages such as Imaris Bitplane for scoring of extravasation.
settings (Supplementary

Tracking extravasation kinetics (Steps 20 and 32).
If desired, kinetic data from single cells or clusters of extravasating cells can be quantified in a moderate-throughput manner via timelapse imaging. The user can observe and differentiate between detailed morphological states such as initial tumor cell protrusion past the endothelium and complete transmigration (Fig. 4,  Supplementary Video 1) . Such information can provide valuable insight into differences in extravasation kinetics that is not possible to obtain with end-point measurements. Generally, a magnification of ~20× is sufficient to visualize these details, with time intervals as small as 5 min, depending on the number of cells to be imaged. Such imaging is facilitated by the short distance (between 170 and 210 µm) between the outer bottom surface of the device and the plane of the µVNs. In addition, temporal and spatial organization of intracellular or extracellular proteins can be resolved, provided that proteins of interest are fluorescently labeled before imaging. Depending on the desired level of resolution, imaging of some cellular proteins (e.g., F-actin, VE-cadherin, focal adhesion proteins) may require higher magnification (>30×), at the cost of increased imaging duration (Fig. 5) .
Immunofluorescence staining (Steps 21-28). Devices can be fixed and processed for immunofluorescence staining at any desired time point, in a manner similar to that used for tissues. One key advantage is the low volume of reagents required (<30 µl of diluted antibody solutions per device), rendering the method an economical choice, especially when large numbers of targets or samples are involved and/or when antibodies are particularly costly or rare. High spatial resolution can be achieved-for example, the position of transmigrating tumor cells relative to the vascular basement membrane can be assessed by staining for proteins such as collagen IV and laminin (Fig. 6) . The ability to generate these data may be valuable, as it has recently been found that proteaselocalizing invadopodia can mediate extravasation, suggesting that basement membrane degradation may be required for complete transmigration.
Tracking tumor cell proliferation and early micrometastasis formation. Tumor cells can also be tracked after extravasation by continued culture of the endothelial-tumor cell system for periods up to 5-6 d post tumor seeding. Paracrine factors secreted by supporting FBs maintain stable µVNs longer than HUVEC monoculture, with the latter experiencing vessel regression as little as 3 d post endothelial seeding 4 . By means of time-lapse microscopy or time-point imaging, the number of tumor cells can be quantified In all experiments, the percentage of extravasation was determined at an end point of 8 h post injection. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; error bars = s.e.m. Ctr, control; NS, not significant. 
Alternative methods
Conventional in vivo extravasation assays. Current in vivo and ex vivo models for visualizing extravasation include mouse [11] [12] [13] [14] [15] , zebrafish 16 and chorioallantoic membrane assays [17] [18] [19] . Although murine models remain the gold standard for recapitulating metastatic seeding, the organs in which tumor cells arrest are often not sufficiently optically accessible for easy live single-cell imaging, rendering it difficult to assess extravasation rates; these are more suitable for end-point ex vivo analyses 14, 15 . Chorioallantoic membrane and zebrafish assays have previously been demonstrated to be much more optically accessible, partly because of the 'planar' nature of the capillary beds, allowing intravascular and extravasated cells to be more clearly differentiated. However, the ability to resolve the dynamics of tumor cell protrusion kinetics with a large number of data points is still limited, probably because of the technical challenges associated with tumor cell injection and live imaging in intact organisms. Quantification of extravasation events in murine systems is often subjective because of the tortuosity of in vivo vasculature (particularly in the lung), while precise measurements rely on high-resolution imaging (60×), greatly increasing data collection times and rendering them generally unsuitable for highly parametric studies. One frequently used method to score extravasation is by counting how many tumor cells are retained in the lung at a certain time after tail-vein injection, with the assumption that extravasated cells will remain detectable, whereas nonextravasated cells are lost because of shear flow or immune factors. However, recent analysis of mouse lung tissues fixed at 24 and 48 h after tailvein injection reveal a nonnegligible proportion of 'retained' tumor cells to be intravascular, and thus these assumptions are questionable 20 . Furthermore, all the above systems feature nonhuman host cells, which may be problematic if specific human tumor-human host cell interactions are not conserved, particularly in the case of various types of immune cells. Last, intravenous injection of tumor cells into most of these systems often requires substantial technical expertise or specialized equipment, which can limit the number of qualified users and even compromise the reproducibility of results. Moreover, procedures such as intracardiac injection of tumor cells often result in a very small number of tumor cells found in the sites of dissemination, rendering it difficult to gather a sufficient number of data points.
Conventional in vitro monolayer-based extravasation assays.
In vitro tools have proven invaluable for the investigation of cellular interactions, as they allow observation of discrete events from a complex cascade, tight control of experimental parameters and exclusive use of human cell lines. The most commonly used model to study extravasation is the Boyden chamber/Transwell assay, in which an endothelial cell monolayer is grown to confluence on a porous insert, followed by the seeding of tumor cells on top of the layer. The number of cells transmigrated can be quantified by collecting the cells that migrate to the underside of the membrane 21, 22 . More recently, similar assays incorporating a 3D ECM matrix beneath the endothelial monolayer have increased the physiological relevance by recapitulating the subendothelial ECM into which tumor cells transmigrate 23 . However, in many of these assays, extravasation cannot be observed in real time or in high resolution, and quantitative assessment is limited to end-point measurements. Microfluidic models of the human vasculature have emerged as a potentially useful tool for studying tumor cell-endothelial cell interactions. For instance, 'networks' of vessels can be formed by lining lithography-based ECM templates (formed via pin pullout 24 , sacrificial gels 25 or 3D printing 26 ) with an endothelial monolayer. Alternatively, endothelial monolayers can be grown in a microfluidic channel to allow application of relevant fluid shear stresses, whereas tumor cell adhesion and transmigration are monitored dynamically 27, 28 . In one approach, an endothelium can be grown perpendicular to the plane of view on the surface of ECM hydrogels held in place via surface tension [29] [30] [31] [32] [33] [34] . This type of assay is particularly amenable to imaging of tumor cell morphological dynamics, as migration occurs in the plane of view; however, the details of the endothelium during transmigration are compromised (such as morphological dynamics of endothelial junctions). A unique advantage to these platforms is their ability to incorporate chemical gradients orthogonal to the endothelial barrier, which may be useful in testing hypotheses involving the dependence of transmigration on chemotactic agents. However, in these assays, the number of observable transmigration events is often limited because of the small surface areas between posts, frequent sprouting of ECs into the gel, and difficulties in ensuring a continuous monolayer at the junction of the PDMS posts and the hydrogel surface. Confirming the barrier integrity at each of these points via diffusive permeability measurements would be laborious, but it is an essential step if the assay is to be used for extravasation studies. Conversely, dextran perfusion in our microvascular network assays shows that vessels are nearly always free of such artifactual focal leaks, suggesting patent lumens at nearly all possible transmigration points. Moreover, the majority of monolayer extravasation systems face challenges, including an artifactual dependence of transmigration rates on the degree of endothelial confluency and geometrical oversimplification as extravasation occurs in complex 3D µVNs with vessel segments of 5-30 µm in diameter instead of >100 µm (ref. 25) or an 'infinite' flat plane of endothelial cells 29, 31 . In addition, in many monolayer systems (especially Transwell filters), nearly all tumor cells seeded at t = 0 will translocate across a monolayer over a 24-to 48-h time frame 35 . As compared with much lower extravasation rates of 40-60% at 24 h that are typically found in mouse 20, 36 and zebrafish 37 models for a variety of cell lines, this suggests that endothelial monolayers exhibit much greater permissiveness to tumor cells as compared with in vivo microvasculature. We note, however, that this value can vary widely depending on the cell type and in vivo model used. Conversely, we have found that the present assay exhibits decreased permissiveness to tumor cells (such as MDA-MB-231) as compared with many endothelial monolayer assays, and exhibits values similar to those found in various mouse models (also for MDA-MB-231) 20, 36 . Furthermore, our measurements of diffusive permeability to 70 kDa dextran reveal a generally higher barrier function than those For all experiments, each point represents one device. **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars = s.e.m. One of the limitations is the general inability of in vitro systems to fully recapitulate the in vivo scenario. For instance, the early metastatic seeding and extravasation microenvironment is characterized by a range of host cells and factors such as platelets and leukocytes, with which tumor cells have been found to interact during transit in vivo 10, 40, 41 . However, the devices are flexible enough to accommodate increased complexity of the microenvironment in order to achieve greater accuracy of the model. For instance, tumor-immune cell interactions can be studied via isolation of platelets or leukocytes from whole human blood followed by perfusion in conjunction with tumor cells, a preliminary demonstration of which is shown in Figure 7 . In fact, the reductionist nature of such an in vitro system can be highly beneficial when one is required to parse out specific interactions independent of the effect of other cell types; this would be more difficult in vivo as it requires either complete ablation or loss of function of endogenous cells. Another limitation is that although soft-lithography techniques are widespread among bioengineering labs there are fewer biology/cancer research labs that perform soft lithography on a routine basis. However, protocols of PDMS-based device fabrication are now well established and robust, and require only several pieces of easily accessible equipment such as a degasser, an 80 °C oven and a plasma etcher. The photo-mask of the device design is accessible in the Supplementary Data, and fabrication of molds can be easily outsourced to companies (e.g., FlowJEM) if in-house fabrication is not available.
• • • HUVECs and 1 × 10 6 FBs are required for a total of 12 devices). Cell numbers can be scaled accordingly if more or fewer devices are to be seeded. Use lower-passage HUVECs (<P8) for best µVN formation results, as endothelial cells become more senescent as passage number increases. Take care as to not allow HUVECs to become overconfluent before trypsinization. Resuspension medium Add 40 µl of thrombin stock solution to 1 ml of EGM-2MV to make a 4 U/ml thrombin solution. Make this solution immediately before device seeding and do not reuse. EQUIPMENT SETUP Preparation of humidity chambers Prepare humidity chambers for device seeding by filling pipette-tip boxes (with a removable rack) with water and autoclaving the whole box for 20 min. Set aside to cool, and then transfer to a 37 °C incubator until time of device seeding. proceDure pDMs device fabrication • tiMinG 24 h 1| Fabricate the microdevice master using the photo-mask pattern provided in the supplementary Data. Wafers can be made via SU-8 micropatterning methods that are established and detailed elsewhere 42 or via outsourcing. A channel height between 110 and 150 µm is optimal for the volumes and cell densities in this given protocol. Silanize the wafer overnight in a vacuum desiccator.
2|
Fabricate and sterilize PDMS devices using the procedure outlined in our previous protocol (Steps 9-26 in Shin et al. 2 ). We recommend punching 3-mm-diameter holes for the media reservoirs and 1-mm-diameter holes for the gel injection ports (Fig. 1c) . Incubate bonded devices at 80 °C for >24 before seeding to ensure that hydrophobicity is restored.  critical step Make sure to keep devices in sterile conditions until opening the device container under a sterile cell culture hood. 4| Add 8 µl of premade fibrinogen solution to 0.5-ml Eppendorf tubes. The number of aliquots made should be 2× the number of devices that will be seeded. For each device to be seeded, one aliquot will be designated for HUVEC injection, whereas the other will be designated for FB injection. Keep aliquots on ice.  critical step A separate aliquot of fibrinogen should be made for each device because once thrombin is added to fibrinogen gelation can occur in < 30 s.
5|
Trypsinize HUVECs and FBs with 0.05% Trypsin-EDTA for 3 min, neutralize with EGM-2MV and centrifuge at RT 5 min at RT 200g.
6|
Aspirate the medium from the cell pellets and resuspend the cells at 12 × 10 6 /ml (HUVECs) and 6 × 10 6 /ml (FBs) in resuspension medium.  critical step Keep resuspended cells on ice during the remaining procedure (not longer than 1 h).  critical step Make sure to aspirate as much of the supernatant as possible (e.g., by waiting a few seconds and aspirating the residual media), as the error in resuspended cell density can be easily increased and propagated when working with small volumes.
7| Mix 8 µl of HUVEC suspension with 8 µl of a fibrinogen aliquot by pipetting up and down 4 or 5 times inside the 0.5-ml Eppendorf tube. Withdraw 10 µl and immediately inject the HUVEC-gel mixture into the center gel region by slowly pipetting it (using a P10 pipette) via one injection port until the solution reaches the start of the narrower downstream channel. Retract the pipette tip slowly without releasing the injector. Repeat this process with the FBs by injecting the FB-fibrinogen mixture into the two flanking channels.  critical step The cell-gel mixture must be injected slowly in order to prevent leakage into the media channels or gel fiber alignment.  critical step Do not reuse the leftover fibrinogen-thrombin mixture in the aliquot for a subsequent device. Even if the leftover aliquot is still 'liquid,' injection of this leftover solution may result in gel fiber alignment in the device because the solution has already begun to polymerize. ? trouBlesHootinG protocol extension nature protocols | VOL.12 NO.5 | 2017 | 873 8| View the device in a sterile Petri dish under a phase-contrast or bright-field microscope to ensure that gels are intact and cells are homogeneously seeded.  critical step Ensure that the device is not 'underfilled.' The gel-media interface formed between the interpost region and the media channel must be flat; otherwise, subsequent introduction of medium into the media channel will result in bubble formation. ? trouBlesHootinG 9| Place the finished device into the humidity chamber and allow gelation for 15 min at RT. While waiting, repeat Steps 7-9 with the rest of the devices.  critical step Ensure that the cell solution is well mixed before withdrawing 8 µl each time, as cells will sink to the bottom of the tube quickly, resulting in inhomogeneous seeding densities. ? trouBlesHootinG 10| After gel polymerization, remove the device from the humidity chamber and wipe the condensation from the glass bottom with a paper towel misted with 70% ethanol. Place the device into a Petri dish and fill the media channels with EGM-2MV by forming a tight seal around the media port with the pipette tip. Depending on the size of the reservoir punched, the pipette tip may have to be cut to size in order to form a seal. Inject the medium until all reservoirs are filled. Repeat with the remaining devices. ? trouBlesHootinG 11| Culture the devices at 37 °C and 5% CO 2 . ? trouBlesHootinG 12| Change the medium in the devices every 24 h by aspirating each media reservoir with a fine-tipped gel-loading tip. Then fill all reservoirs on one side with medium, and wait until the medium has flowed down the channel, causing the media levels to rise in the opposing reservoir. Top off the reservoirs with more medium until they are full. µVNs will be ready to perfuse after 4 to 5 d of culture. 
15|
If live imaging will later be performed to track extravasation, HUVECs should be fluorescently labeled to robustly differentiate between intravascular and extravascular cells. It is recommended that HUVECs be transduced to stably express cytoplasmic or membrane fluorescence. The protocol used to generate our stable fluorescent HUVECs is provided in the supplementary Methods. Alternatively, the device can be incubated with CellTracker or DiI solution in EGM-2MV for 1 h at 37 °C and 5% CO 2 . Apply a hydrostatic pressure drop across the HUVEC gel region to help the dye penetrate the entire µVN. A pressure drop of 4 mm H 2 O (equivalent to ~38 µl of solution in both reservoirs on one side of the gel region, for a 3-mm diameter reservoir) can be applied to promote convection and thus penetration of the dye throughout the vascular bed. After incubation, wash the device twice with EGM-2MV before proceeding.
16|
We recommend the use of tumor cells that stably express a fluorescent cytoplasmic or membrane marker. If tumor cells are nonfluorescent, label cells with CellTracker or DiI solution following the manufacturer's instructions.
17|
Trypsinize and resuspend tumor cells to a final concentration of 5 × 10 5 cells/ml in EGM-2MV and store on ice until perfusion.
18|
If you are perfusing platelets and/or neutrophils with tumor cells, mix the cells together to achieve the desired ratio.
19|
With a gel-loading tip connected to an aspiration line, withdraw media from all four reservoirs directly flanking the HU-VEC gel region. Mix the tumor cell suspension well, and fill one reservoir with 20 µl of cell suspension. Wait 5 s for the cells to flow down the medial channel (parallel to the gel). Aspirate all reservoirs again and apply 38 µl of cell suspension to both reservoirs on one side (this creates a pressure drop of ~4 mm H 2 O across the vascular bed). The volume should be adjusted if the reservoir diameter is not 3 mm. Cells should now flow across the HUVEC gel region within the lumens because of the pressure drop. Check the device using bright-field or phase-contrast microscopy to ensure that cells are flowing through the µVNs (supplementary Video 2). Flowing cells can be clearly seen even at 10× magnification. Cells should gradually arrest in microvasculature because of size restriction. If vessel openings are small and few tumor cells flow through the capillary bed, use a fine pipette tip on an aspiration line to gently aspirate media from a downstream media port for 1-2 s.  critical step Aspirate gently and with a fine tip so as to not form a tight seal with the media ports, which may cause the media channel to be fully aspirated (rendering the device prone to bubble formation), or cause vessels to rupture.  critical step Ensure that the chamber is well humidified and sealed for the entire duration of the time-lapse to prevent evaporation and cell death. Parafilm can be used to seal crevices and help create a well-contained and humidified chamber. (iii) Allow the device to rest on the specimen holder in the primed environmental chamber for at least 10 min before imaging to allow for thermal equilibration. (iv) While waiting for equilibration of the device, set up the time-lapse parameters. For quantification of extravasation and/or visualization of tumor cell protrusions during extravasation, use at least a 20× objective (we use a numerical aperture of 0.75 and a resolution of 800 × 800) or higher and at least 2-µm z-slice thicknesses. To track protrusion formation, image each region at least once every 20 min or faster, depending on the overall speed of protrusion onset and total translocation time for a particular cell type or condition (Fig. 4) . Set region locations if there are multiple areas of interest in the device. For quantification of extravasation efficiency of one device, select enough regions of interest to span the entire device-this typically yields ~40 to 150 tumor cells per sample. For tracking of tumor cell proliferation, acquire images at least once every 5 h for >24 h. ? trouBlesHootinG (v) Ensure that the chamber is protected from other sources of light and begin the time-lapse imaging.
 critical step Avoid high laser intensities, as this can cause phototoxicity and cell death during imaging. To quantify extravasation rates for a single condition, we advise making the quantification on at least three independent devices per experiment, and preferably over at least two independent experiments (i.e., 6 devices per condition).
32|
To calculate rate of protrusion formation from time-lapse experiments, analyze the status of the protrusion for individual tumor cells at multiple time frames (e.g., 20-min frame intervals). The first time frame at which a cell exhibits protrusion formation past the endothelium can be designated as the 'time of protrusion onset' (Fig. 4a) . The same tumor cell can be followed until the cell has fully transmigrated past the endothelium. The time interval between full body transmigration and the initiation of protrusion can be designated as the 'total time required for transmigration.' 
anticipateD results
This protocol has been used to conduct robust and highly parametric studies of extravasation efficiencies subject to perturbations in either tumor or endothelial cells using various pharmacological agents or genetic perturbations (Fig. 3c) . This is especially useful when sample numbers greatly exceed those that are realistic in an in vivo setting. Although the microvascular network assay cannot replace in vivo extravasation models, it can serve as a rapid and cost-efficient preliminary test of hypotheses, which can later be validated in an in vivo assay. For instance, we have previously assessed the roles of various tumor cell integrins on extravasation efficiency in a panel of tumor cells lines. By means of both function-blocking antibodies and siRNA knockdown of integrins α1, α2, α3, α4, α5, α6 and αv, as well as β1, β3 and β4, we found that tumor cell adhesion to subendothelial laminin via α3 and α6β1 integrins was critical for efficient extravasation. These findings were then validated in a mouse model to confirm attenuation of metastasis formation. Furthermore, higher-resolution confocal microscopy revealed that extravasation is characterized by the recruitment of activated β1 integrin and F-actin to the tips of tumor cell protrusions extending past the endothelium into the surrounding matrix 36 . Combined, we demonstrate the ability to achieve both moderate-throughput quantification and detailed resolution of morphological dynamics of extravasation from a single assay. By increasing the level of complexity of the microdevice, one can further augment the accuracy of the extravasation model. Recently, much attention has been directed to the role of 'pre-metastatic' niches, which consist of complex tumor-host cell interactions during circulation, extravasation and recolonization. For instance, circulating immune cells, including platelets and leukocytes, have been shown to interact with tumor cells, and can act to enhance metastasis 10, 41, 43 . We show that human platelets and leukocytes isolated from whole human blood can be perfused with tumor cells and undergo immunetumor interactions, and the effects on extravasation can be monitored in the microdevices (Fig. 7a,b) . In addition, the contribution of stromal cells such as pericytes can also be investigated by seeding these cells together with HUVECs in the same gel region (Fig. 7c) . There is also increasing evidence favoring the 'seed and soil' theory for metastatic cancer cells, which suggests that some cancer cell types display increased propensity to 'home' to and/or subsequently colonize certain organs. Although the current device cannot be used to model homing processes such as selective arrest (because tumor cells flow into and are physically trapped in the vasculature), it is possible to use the assay to understand how different 
